GlassScriptPhysician profile
Jacinta Okeke
NPI 1861975575
$3,920.54
in general payments reported to CMS, 2019-2025
22 companies · $1,524 in 2025
The $1,524 reported for 2025 was more than what 88% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $293 · 2022: $264 · 2023: $577 · 2024: $1,262 · 2025: $1,524.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,336 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,335.78 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $645.68 | 2023-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $491.72 | 2022-2025 | Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $413.99 | 2024-2025 | Invega, Invega Sustenna, Invega Trinza |
| Astrazeneca Pharmaceuticals LP | $362.59 | 2024-2025 | Breztri, Airsupra |
| Incyte Corporation | $334.51 | 2021-2024 | Jakafi |
| Alkermes, INC. | $310.56 | 2023-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $192.22 | 2024-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $146.69 | 2024-2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $126.76 | 2023-2025 | Caplyta |
| Amgen INC. | $125.00 | 2024 | Krystexxa |
| Boston Scientific Corporation | $102.01 | 2025 | Watchman Flx |
| Abbvie INC. | $100.10 | 2021-2023 | |
| Abbott Laboratories | $96.87 | 2023 | Freestyle Libre 3 |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $94.08 | 2024-2025 | Lifevest |
| Evoke Pharma, INC. | $81.21 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $76.14 | 2021 | |
| Esperion Therapeutics, INC. | $74.98 | 2021 | |
| Medtronic, INC. | $39.14 | 2023 | Corevalve Evolut R |
| Novo Nordisk INC | $31.90 | 2025 | Ozempic |
| Janssen Scientific Affairs, LLC | $25.02 | 2025 | Invega Sustenna |
| Luye Pharma (USA) LTD. | $24.91 | 2025 | Erzofri Extended-Release |
| Noven Therapeutics, LLC | $24.46 | 2024 | Xelstrym, Secuado |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacinta Okeke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.